SLPI Double Nickase Plasmid (h): sc-418559-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SLPI Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- SLPI Double Nickase Plasmid (h) and SLPI Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting SLPI. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: SLPI Antibody (F-12): sc-373802
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SLPI Double Nickase Plasmid (h) | sc-418559-NIC | 20 µg | $410.00 | |||
SLPI Double Nickase Plasmid (h2) | sc-418559-NIC-2 | 20 µg | $410.00 |
Secretory leukocyte peptidase inhibitor (SLPI) is a small, secreted serine protease inhibitor that helps maintain epithelial and mucosal barrier homeostasis by limiting the activity of neutrophil elastase, cathepsin G, and related proteases. Beyond antiprotease function, SLPI can modulate innate immune signaling and inflammatory gene expression, influencing processes such as wound repair, antimicrobial defense, and leukocyte recruitment. Altered SLPI expression has been reported in inflammatory airway and skin conditions, chronic mucosal inflammation, and infection-associated tissue remodeling, making it a useful molecular node for studying protease–antiprotease balance. SLPI is therefore relevant to research on epithelial biology, immune regulation, and microenvironmental factors that shape disease-associated inflammation.
SLPI Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the SLPI locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within SLPI. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt SLPI function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of SLPI-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.